Here, we outline the case for the integration of epigenetic measures, in the form of blood-based DNA methylation marks, into existing risk prediction models using the example of BRCA1, the breast cancer susceptibility gene with the highest penetrance, to illustrate the gaps in our knowledge that need to be addressed to improve clinical risk assessment. The gene discussed is BRCA1; the disease is breast cancer.